Current status of low density lipoprotein-apheresis for the therapy of severe hyperlipidemia.
The use of LDL-apheresis to treat patients with severe hypercholesterolemia has gained wider clinical acceptance during the past 2-3 years, particularly in patients with coronary artery disease. Systems utilizing immunoadsorption columns, dextran sulfate cellulose columns and heparin precipitation have been most commonly employed. New or improved technologies include whole-blood compatible columns, double-filtration plasmapheresis and lipoprotein (a)-apheresis. The mechanisms for clinical improvement extend beyond simple regression of atherosclerotic plaque.
Gordon
B R
BR
Rogosin Institute, New York Hospital-Cornell Medical Center, New York 10021, USA.
Saal
S D
SD
D001781:Blood Component Removal; D002986:Clinical Trials as Topic; D006801:Humans; D006937:Hypercholesterolemia / Q000628:therapy*; D008077:Lipoproteins, LDL / Q000097:blood / Q000302:isolation & purification*; D016896:Treatment Outcome
D008077:Lipoproteins, LDL